ReviewAging clinical and experimental research2016
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.
Review in Aging clinical and experimental research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 6 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Evidence-based position paper on Physical and Rehabilitation Medicine (PRM) professional practice for persons with sarcopenia. The European PRM position (UEMS PRM Section).European journal of physical and rehabilitation medicine · 2026Pooled it
- Use of the Ishii Test for screening sarcopenia in older adults: a systematic review with meta-analysis of diagnostic test accuracy (DTA) studies.BMC geriatrics · 2024Pooled it
- Sarcopenia and health-related quality of life: A systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Effect of Angiotensin System Inhibitors on Physical Performance in Older People - A Systematic Review and Meta-Analysis.Journal of the American Medical Directors Association · 2021Pooled it
- Efficacy of School-Based Interventions for Improving Muscular Fitness Outcomes in Adolescent Boys: A Systematic Review and Meta-analysis.Sports medicine (Auckland, N.Z.) · 2020Pooled it
- Effects of Protein, Essential Amino Acids, B-Hydroxy B-Methylbutyrate, Creatine, Dehydroepiandrosterone and Fatty Acid Supplementation on Muscle Mass, Muscle Strength and Physical Performance in Older People Aged 60 Years and Over. A Systematic Review on the Literature.The journal of nutrition, health & aging · 2018Pooled it
- School-Based Comprehensive Strength Training Interventions to Improve Muscular Fitness and Perceived Physical Competence in Chinese Male Adolescents.BioMed research international · 2022Trial
- Progressive Resistance Training Improves Torque Capacity and Strength in Mobility-Limited Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Trial
- Development of pharmacological interventions for the treatment of sarcopenia.Annals of translational medicine · 2026Review
- The predictive values of sarcopenia screening tools in preoperative elderly patients with colorectal cancer: applying the diagnostic criteria of EWGSOP2 and AWGS2019.BMC geriatrics · 2025Article
- The role of sarcopenic obesity for the prediction of prognosis of patients with gastrointestinal cancer.Cancer medicine · 2024Article
- Longitudinal assessment of the relationship between frailty and social relationships among Japanese older adults: a random intercept cross-lagged panel model.BMC public health · 2024Article
- Towards a core outcome set (COS) for intrinsic capacity (IC) intervention studies in adults in midlife and beyond: a scoping review to identify frequently used outcomes and measurement tools.Aging clinical and experimental research · 2024Article
- The Current Landscape of Pharmacotherapies for Sarcopenia.Drugs & aging · 2024Article
- Obstacles to the Early Diagnosis and Management of Sarcopenia: Current Perspectives.Clinical interventions in aging · 2024Review
- The relationship between loneliness and healthy aging indicators in Brazil (ELSI-Brazil) and England (ELSA): sex differences.Public health · 2023Article
- COVID-19 in Older Patients: Assessment of Post-COVID-19 Sarcopenia.Biomedicines · 2023Article
- Accuracy of handgrip and respiratory muscle strength in identifying sarcopenia in older, community-dwelling, Brazilian women.Scientific reports · 2023Article
- Homing in on cognition with cross-sectional analysis of sarcopenia-related measurements: the SARCOG study.Aging clinical and experimental research · 2022Article
- Sarcopenia as Manifested by L3SMI Is Associated with Increased Long-Term Mortality amongst Internal Medicine Patients-A Prospective Cohort Study.Journal of clinical medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 19 institutions in 9 countries.
Funding
Abstract
purposeSarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities.
methodsA multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication.
resultsA case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia.
conclusionsThe current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.